PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals (TEVA) announced a voluntary recall of seven lots of Amikacin Sulfate Injection USP, 500 mg/2mL (250 mg/mL) and 1 gram/4mL (250 mg/mL) vials due to the potential for the presence of glass particulate matter. The company said, to date, it has not received any reports of adverse events or complaints related to the recall.
Teva has issued an Urgent Drug Recall Letter to their direct customers. The company is arranging for impacted product to be returned to Inmar.
Copyright RTT News/dpa-AFX